Skip to main content
EJNMMI Research
Fig. 3 | EJNMMI Research

Fig. 3

From: Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine

Fig. 3

Biodistribution comparison of 213Bi-DOTATATE (0.3 nmol) with (w) or without (wo) l-lysine (35 mg) pre-injection. a AR42J tumor-bearing animals 10 min p.i. b AR42J tumor-bearing animals 60 min p.i. c Nontumor-bearing animals 10 min p.i. d Nontumor-bearing animals 60 min p.i., n = 5. The uptake was expressed as percentage of injected activity per gram of tissue (%IA/g)

Back to article page